tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cellectis price target raised to $8 from $4 at Barclays
PremiumThe FlyCellectis price target raised to $8 from $4 at Barclays
2M ago
Cellectis SA’s Promising Study on UCART20x22 for B-Cell Non-Hodgkin Lymphoma
Premium
Company Announcements
Cellectis SA’s Promising Study on UCART20x22 for B-Cell Non-Hodgkin Lymphoma
3M ago
Cellectis SA: Hold Rating Amid Upcoming Data Presentations and Financial Considerations
Premium
Ratings
Cellectis SA: Hold Rating Amid Upcoming Data Presentations and Financial Considerations
4M ago
Cautious Hold on Cellectis SA Amid Anticipated Data Releases and Strategic Developments
PremiumRatingsCautious Hold on Cellectis SA Amid Anticipated Data Releases and Strategic Developments
7M ago
Cellectis SA: Hold Rating Amid Stable Financials and Promising Collaborations, Yet Cautious Outlook Due to Market and Clinical Uncertainties
Premium
Ratings
Cellectis SA: Hold Rating Amid Stable Financials and Promising Collaborations, Yet Cautious Outlook Due to Market and Clinical Uncertainties
7M ago
Cellectis price target lowered to $4 from $5 at Barclays
Premium
The Fly
Cellectis price target lowered to $4 from $5 at Barclays
7M ago
Cellectis SA: Strategic Collaborations and Clinical Advancements Drive Buy Rating
PremiumRatingsCellectis SA: Strategic Collaborations and Clinical Advancements Drive Buy Rating
9M ago
Cellectis Reports 2024 Financial Results and Strategic Advances in CAR T-Cell Therapies
Premium
Company Announcements
Cellectis Reports 2024 Financial Results and Strategic Advances in CAR T-Cell Therapies
9M ago
Cellectis Advances Clinical Programs and Strengthens AstraZeneca Partnership
Premium
Company Announcements
Cellectis Advances Clinical Programs and Strengthens AstraZeneca Partnership
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100